Pharmaceutical formulation
US6245352A · kind A · utility
14Cited by
2References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 14, 1999 |
| Grant date | Jun 12, 2001 |
| Priority date | — |
| Expiry date | Dec 14, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/2077
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a pharmaceutical formulation, which comprises from 5 to 15% by weight of tamoxifen citrate and a first disintegrant which is croscarmellose sodium, the percentage by weight of croscarmellose sodium present in the formulation being chosen such that, in six 20 mg unit doses, an average of at least 65 percent by weight of the tamoxifen citrate in the formulation will dissolve within 10 minutes in 1000 mL of 0.02N hydrochloric acid at 37.degree. C. when stirred at 100 rpm.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.